Dillon Cockrell, GU Medical Oncologist at Duke Cancer Institute, shared a post on X:
“Big presentation of Day 2 at ASCO26 is TALAPRO3 from Neeraj Agarwal, also published in NEJM. Phase 3 for ADT/enzalutamide +/- talazoparib for mHSPC with HRR alteration.
Primary endpoint met with rPFS (HR 0.48). OS trending favorably but immature. MDS/AML was seen as part of tala toxicity again.
Subgroups generally favor adding tala but most notable in BRCA2, ATM, and CDK12.
All metastatic Prostate Cancer patients need genomic testing as part of treatment planning. Adding PARP is reasonable for HRR mutated disease but comes with cumulative toxicity risk.”
Other articles featuring Dillon Cockrell on OncoDaily.
